ADHD Medications May Help Ease Menopausal Brain Fog

Recent findings suggest that medications typically used to treat attention-deficit/hyperactivity disorder (ADHD) could alleviate symptoms of brain fog experienced by women during menopause. This was highlighted in a review presented at the 2026 Annual Meeting of the Menopause Society, though the results have yet to be published in a peer-reviewed journal.

The review indicates that drugs like lisdexamfetamine (Vyvanse) and atomoxetine (Strattera) may enhance self-reported cognitive functions, such as memory and focus, in women who are perimenopausal or postmenopausal. However, objective cognitive assessments showed minimal to no improvement with these medications.

Brain fog, characterized by forgetfulness, slower cognitive processing, and difficulty concentrating, is a common complaint among women undergoing menopause. These symptoms, often attributed to fluctuating hormone levels, particularly estrogen, can significantly disrupt daily life. As estrogen levels decline, the balance of neurotransmitters like dopamine and norepinephrine in the brain may be affected, leading to cognitive challenges.

While the preliminary findings of the review are intriguing, experts warn that it is premature to endorse ADHD medications for menopausal brain fog. Dr. Sara Vaughn, Chief Medical Officer at Clair Health, emphasized that while the results are promising, they do not provide sufficient evidence to establish these medications as a treatment option for brain fog associated with menopause.

The review included five studies focusing on women aged 45 to 60, assessing how ADHD medications influenced cognitive outcomes. Results showed that with lisdexamfetamine, self-reported ADHD symptoms decreased notably, but there was no significant change in objective cognitive measures like memory and processing speed. Similarly, atomoxetine produced a reduction in perceived symptoms but did not translate to improved performance on formal tests.

Dr. Vaughn noted that the review’s limitations include a small number of studies and reliance on self-reported data, which can introduce bias. Additionally, since the FDA has not approved these medications for managing menopausal symptoms, their use would be considered off-label, raising potential safety concerns such as cardiovascular risks and the possibility of misuse.

Experts recommend further research, including long-term studies, to better understand the relationship between menopausal cognitive symptoms and ADHD. They also encourage clinicians to screen for ADHD in women experiencing cognitive difficulties, as undiagnosed cases may contribute to worsening symptoms.

In the meantime, women dealing with menopausal brain fog can incorporate lifestyle changes to help manage symptoms. The National Council on Aging advises maintaining a nutrient-rich diet, engaging in regular physical activity, and exercising the brain through puzzles and new hobbies.

Overall, while the potential for ADHD medications to alleviate menopausal brain fog is an exciting development, caution is warranted until more comprehensive research establishes clear treatment protocols.